The PPARγ agonist rosiglitazone prevents neuronal loss and attenuates development of spontaneous recurrent seizures through BDNF/TrkB signaling following pilocarpine-induced status epilepticus.

Sun Hong,Yu Xin,Wu HaiQin,Zhang GuiLian,Zhang Ru,Zhan ShuQin,Wang HuQing,Yao Li,Bu Ning,Li YongNan

DOI: https://doi.org/10.1016/j.neuint.2013.07.010

IF: 4.297

2013-01-01

Neurochemistry International

Abstract:•Rosiglitazone inhibited increases in BDNF and TrkB after SE, and also prevented hippocampal neuronal loss.•Rosiglitazone potently suppressed SRS after SE, but did not affect the development and severity of SE.•Rosiglitazone exerts neuroprotective and antiepileptic effects through BDNF/TrkB signaling.